Business Development Containment Contract Manufacturing Development 
Pharmaceutical Technology
SEPTEMBER 8, 2022
Streamlined development, flexibility in manufacturing, and improved product quality at reduced costs, while gaining access to capabilities and capacity are some of the factors fuelling the pharmaceutical solid dosage contract manufacturing market.
Pharmaceutical Technology
SEPTEMBER 15, 2022
Research by GlobalData (Contract Small Molecule API Manufacturing Industry by the Numbers – 2021 Edition) shows that containment facilities are in high demand as the use of cytotoxic drugs continues to grow. This suggests a move towards high-value specialised manufacturing. Containment challenges.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmaceutical Technology
SEPTEMBER 14, 2022
Pharmaceutical drug research and development (R&D) activities are capital-intensive, which makes the outsourcing of clinical dose manufacturing and marketing popular. The download contains detailed information on the providers and their services and solutions, alongside contact details to aid your purchasing or hiring decision.
Pharmaceutical Technology
SEPTEMBER 14, 2022
The dose form manufacturing follows API manufacturing to produce the final dosage form (FDF such as tablets and injectables. Commercial dose companies in contract marketing help in strategically positioning the products in the market, enabling patients to reap maximum benefit from it and transforming its sales management strategies.
The Pharma Data
NOVEMBER 5, 2020
Business Highlights. Key Pipeline Progress Regeneron has more than 20 product candidates in clinical development, including five marketed products for which it is investigating additional indications. Corporate and Business Development Update. Research and development (R&D). $. government. Operating Expenses.
The Pharma Data
NOVEMBER 15, 2020
Prior to Celgene, she held leadership roles in marketing, sales and new business development from 2002 to 2011 at Johnson & Johnson. Shah previously served as Chief Executive Officer and a member of the board of directors of BioMotiv, an accelerator company aligned with the Harrington Project for Discovery & Development, a U.S.
The Pharma Data
MAY 4, 2021
to $3.65, Primarily Reflecting Updates to Anticipated Contributions from BNT162b2 Partially Offset by Additional R&D Expenses for Vaccines to Protect Against COVID-19 as Well as Other mRNA-Based Development Programs and COVID-19 Antivirals. Billion Doses Expected to be Delivered in 2021 Under Signed Contracts as of Mid-April 2021.
Expert insights. Personalized for you.
100 
Let's personalize your content